Table 1.

The 10 most cited papers in lung cancer radiotherapy from 2000 to 2022^a.

Rank	Title	Corresponding Author	Journal	Year	Total citations	Average citations per year (rank)
1	Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer	Antonia SJ	N. Engl. J. Med.	2017	2110	436.55 (1)
2	Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer	Timmerman R	JAMA-J. Am. Med. Assoc.	2010	1805	144.4 (6)
3	Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer	LeChevalier T	N. Engl. J. Med.	2004	1732	92.79 (13)
4	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC	Antonia SJ	N. Engl. J. Med.	2018	1358	362.13 (2)
5	Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study	Bradley JD	Lancet Oncol.	2015	1240	163.52 (4)
6	Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial	Douillard JY	Lancet Oncol.	2006	1153	72.06 (18)
7	Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer	Timmerman R	J. Clin. Oncol.	2006	1074	67.48 (23)
8	Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial	Albain KS	Lancet	2009	993	75.9 (15)
9	Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation	Dennis PA	Cancer Res.	2001	812	38.06 (62)
10	Lung Cancer: Epidemiology, Etiology, and Prevention	DelaCruz CS	Clin. Chest Med.	2011	802	74.6 (16)